Biologics in Wound Management
- 23 Downloads
Biologics are a new class of drugs which mimic the action of human proteins and interact with circulating proteins or cellular/extracellular targets, blocking their activities. The main application of biologics in dermatology concerns psoriasis, atopic dermatitis, and recently hidradenitis suppurativa, with a growing interest in chronic wound management. Inflammatory wounds such as pyoderma gangrenosum and vasculitic ulcers are the main indications for biologics, according to the pathogenesis of them. Wondering the use of this drugs we have to consider the possible contraindications, side effects, and the remarkable costs. Checking the literature we can find just case reports or small case series about their use in chronic wound therapy.
KeywordsBiologics Chronic wounds Skin ulcers Pyoderma gangrenosum Vasculitic ulcers
Conflict of Interest
The authors declare no conflict of interest.
- 15.Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035–50.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Chung ES, Packer M, Lo KH, FaSanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of ifx, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133–40.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Choucair MM, Fivenson DP. Pyoderma gangrenosum: a review of the disease and treatment options. Wounds. 2001;13(3):119–22.Google Scholar
- 25.Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings & Alex Ortega-Loayza. Biologic and small molecule medications in the management of pyoderma gangrenosum, J Dermatolog Treat. 2018Sep 7;Epub.Google Scholar
- 28.Ntatsaki E., Carruthers D., Chakravarty K., et al. BSR and BHPR guideline for the 316 management of adults with ANCA-associated vasculitis, rheumatology. Oxford. 2014;317.Google Scholar
- 29.Charles P., Bienvenu B., Bonnotte B., et al. Rituximab: recommendations of the 319 French Vasculitis Study Group (FVSG) for induction and maintenance treatments 320 of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides, 321 Presse Med. 2013;42(10):1317–1330.Google Scholar
- 33.Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Fox JD, Baquerizo-Nole KL, Keegan BR, Macquhae F, Escandon J, Espinosa A, Perez C, Romanelli P, Kirsner RS. Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study. Int Wound J. 2016;13(5):963–6. Google Scholar